Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Heparinase-Modified Thrombelastometry: Inactivation of Heparin in Plasma Samples

Cvirn, G.; Tafeit, E.; Hoerl, G.; Janschitz, M.; Wagner, T.; Juergens, G.; Koestenberger, M.

Clinical Laboratory 56(11-12): 585-589

2010

ISSN/ISBN: 1433-6510
PMID: 21141445
Document Number: 12878
Background: The heparinase-modified thrombelastometry (HEPTEM) assay is a promising tool to assess the coagulation status of heparinised patients. The aim of our study was to examine the heparin neutralizing capability of the HEPTEM assay in plasma samples. Methods: In the HEPTEM assay, blood or plasma samples become activated via the intrinsic pathway in the presence of a heparin processing enzyme. Results: We examined coagulation times (CTs) in the presence of increasing amounts (0 - 4 IU / mL) of heparin. We found that up to a concentration of 0.5 IU / mL, heparin is completely neutralized. However, CTs increased linearly in the presence of heparin concentrations higher than 0.5 IU / mL, indicating incomplete heparin neutralization in the standard HEPTEM assay. Conclusions: We provide herein a mathematical procedure to correct the misleadingly prolonged CTs (for heparin > 0.5 IU / mL) for the HEPTEM assay performed in plasma samples to allow better estimation of the coagulation status in patients requiring intense anticoagulation (e.g. patients undergoing cardiac surgery).

Document emailed within 1 workday
Secure & encrypted payments

Heparinase-Modified Thrombelastometry: Inactivation of Heparin in Plasma Samples

Clark, M.; Hoppensteadt, D.; Walenga, J.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J. 2008: Molecular profiling of heparinase-i resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate International Angiology: a Journal of the International Union of Angiology 27(5): 370-376
Weiler, J.M.; Edens, R.E.; Linhardt, R.J.; Kapelanski, D.P. 1992: Heparin and modified heparin inhibit complement activation in vivo Journal of Immunology 148(10): 3210-3215
Eastwood, J.B.; Phillips, M.E.; Minty, P.; Gower, P.E.; Curtis, J.R. 1983: Heparin inactivation, acidosis and copper poisoning due to presumed acid contamination of water in a hemodialysis unit Clinical Nephrology 20(4): 197-201
Manásková, P.; Mészárosová, A.; Liberda, J.; Voburka, Z.; Tichá, M.; Jonáková, V. 1999: Aggregated forms of heparin-binding and non-heparin-binding proteins of boar seminal plasma and their binding properties Folia Biologica 45(5): 193-201
Egberg, N.; Gallimore, M.J. 1983: Studies on Hageman factor, plasma prekallikrein, kallikrein "like" activity and kallikrein inhibition in plasma samples from normal subjects and clinical material Advances in Experimental Medicine and Biology 156: 1109-1117
Pogliani, E.M.; Cofrancesco, E.; Salvatore, M.; Boschetti, C.; Cortellaro, M. 1985: High fibrinopeptide a levels modified by heparin in acute nonlymphocytic leukemia Thrombosis and Haemostasis 54(3): 727
Hilfenhaus, J.; Niedrig, M.; Nowak, T. 1993: Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives Developments in Biological Standardization 81: 117-123
Agadzhanian, S.A.; Arutiunian, A.A.; Karabashian, L.V. 1984: Identification of a glutamate dehydrogenase amino acid residue modified by 2,2,6,6-tetramethyl-4-oxopiperidine-1-oxyl. Study of the type of inactivation of a catalytically active enzyme oligomer in modification Bioorganicheskaia Khimiia 10(9): 1171-1176
Olofsson, P.; Olofsson, C.; Nylander, G.; Olsson, P. 1987: Endotoxin inactivation in plasma from patients with gram-negative infection--an in vitro study Progress in Clinical and Biological Research 231: 323-330
Mauler, R.; Merkle, W.; Hilfenhaus, J. 1987: Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations Developments in Biological Standardization 67: 337-351
Wang, P.; Ba, Z.F.; Chaudry, I.H. 1994: Chemically modified heparin improves hepatocellular function, cardiac output, and microcirculation after trauma-hemorrhage and resuscitation Surgery 116(2): 169-75; Discussion 175-6
Frégeau, C.J.; Bowen, K.L.; Leclair, B.ît.; Trudel, I.; Bishop, L.; Fourney, R.M. 2003: AmpFlSTR profiler Plus short tandem repeat DNA analysis of casework samples, mixture samples, and nonhuman DNA samples amplified under reduced PCR volume conditions (25 microL) Journal of Forensic Sciences 48(5): 1014-1034
Katznelson, D.; Sack, J.; Frass, M.; Vogt, E.; Hosli, P. 1981: Heat inactivation of plasma hydrolases as a means of discriminating between the genotypes in cystic fibrosis: the experience in Israel Israel Journal of Medical Sciences 17(8): 687-689
White, M.M.; Siders, L.; Jennings, L.K.; White, F.L. 1992: The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia Thrombosis and Haemostasis 68(1): 88
Stancheva, A.; Spassov, L.; Tzatchev, K. 2011: Correlation Between Rotation Thrombelastometry ROTEM® Analysis and Standard Haemostatic Parameters During Liver Transplantation Clinical Laboratory 57(5-6): 407-413
Braat, E.A.; Los, P.; Rijken, D.C. 1998: The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(5): 419-427
Kotovshchikova, M.A.; Krasko, S.S. 1974: Determination of heparin in blood plasma Laboratornoe Delo 8: 460-463
Thompson, A.R.; Counts, R.B. 1976: Removal of heparin and protamine from plasma Journal of Laboratory and Clinical Medicine 88(6): 922-929
Béguin, S.; Lindhout, T.; Hemker, H.C. 1988: The mode of action of heparin in plasma Thrombosis and Haemostasis 60(3): 457-462
Budovskiĭ, E.I.; Zalesskaia, M.A. 1985: Principles of selective inactivation of the viral genome. III. Kinetics of the inactivation of bacteriophage MS2 infectivity by beta-propiolactone Molekuliarnaia Biologiia 19(4): 1139-1147